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Natural Killer (NK) cells boost immune defense via their cytolytic activity and their capacity to produce
interferon-g. Now Perona-Wright et al. (2009), in this issue of Cell Host & Microbe, show that NK cells can
also dampen immune responses to diverse pathogens via secretion of the anti-inflammatory cytokine
interleukin-10. Remarkably, this immunosuppressive activity only occurs during systemic infections.A central theme in the organization of life
resides in feedback loops. Positive and
negative feedback loops exist at molec-
ular and cellular scales and participate to
the emerging properties of living organ-
isms. During innate immune responses,
a positive feedback loop between
dendritic cells (DCs) that produce
interleukin-12 (IL-12) and Natural Killer
(NK) cells that produce interferon-g
(IFN-g) amplifies IL-12-induced IFN-g
secretion and IFN-g-induced IL-12 secre-
tion. Perona-Wright et al. (2009) now
show that during the course of systemic
infections induced by Toxoplasma gondii,
Listeria monocytogenes, and Yersinia
pestis, IL-12 secreted by DC induces NK
cells to produce the broadly immunosup-
pressive cytokine IL-10, which in turn
inhibits IL-12 secretion by DC (Perona-
Wright et al., 2009). Two opposite
feedback loops are thus at play during
innate immune responses (Figure 1),
raising several questions as to the biolog-
ical consequences of this ‘‘duet’’ in
immunity.
NK cells are lymphocytes of the innate
immune system. NK cell-deficient mice
are not reported to present detectable
abnormalities at steady state. Yet NK cells
participate in the early control of virus and
intracytoplasmic parasite infection, to
allogeneic responses, and to antitumoral
immunosurveillance (Vivier et al., 2008).
NK cells have been described to exert
their effector activities through direct
cytotoxicity and the secretion of cytokine,
such as IFN-g. The study by Perona-
Wright and colleagues highlights that NK
cells can also dampen inflammatoryprocesses via the production of IL-10
(Perona-Wright et al., 2009).
IL-10 secretion by NK cells has been
described since many years (Moore
et al., 2001), but interest in this observa-
tion has re-emerged recently. In models
of murine cytomegalovirus infection
(MCMV), the sustained activation of NK
cells leads to the production of IL-10
that in turn limits the magnitude of T cell
response and T cell-mediated immunopa-
thology (Lee et al., 2009). In a mouse
model of visceral leishmaniasis induced
by Leishmania donovani, IL-10-secreting
NK cells are present in spleen and hepatic
granuloma and inhibit host protection
against the parasite (Maroof et al., 2008).
Interestingly, NK cells are detected within
the first 3 days of Toxoplasma gondii
infection as the first and most frequent
IL-10 producers (Perona-Wright et al.,
2009), consistent with the kinetics of
IL-10 production by NK cells reported
during Leishmania donovani infection
(Maroof et al., 2008). Another common
factor to these experimental settings is
that the production of IL-10 by NK cells
appears to be linked to a strong stimula-
tion: high MCMV burden in perforin-defi-
cient mice (intravenous injection) (Lee
et al., 2009); chronic inflammation during
Leishmania donovani infection (intrave-
nous injection) (Maroof et al., 2008); and
systemic infection with Toxoplasma
gondii (gavage), Listeria monocytogenes
(intraperitoneal injection), or Yersinia
pestis (intravenous injection) (Perona-
Wright et al., 2009). Indeed, when mice
are challenged with pathogens that do
not lead to disseminated infection, suchCell Host & Microbe 6, Das influenza virus (intranasal instillation)
or an attenuated nondisseminating Yersi-
nia pestis strain (intranasal instillation),
NK cells secrete IFN-g, but no IL-10
(Perona-Wright et al., 2009). In these
experiments, the production of IL-10 by
NK cells is associated with the intensity
of the IL-12 response. These results
suggest that the ‘‘strength’’ of the
microbial challenge is translated into the
secretion of IL-12, which in turn dictates
the net outcome of the NK cell response:
stimulatory in the case of IFN-g, inhibitory
in the case of a prominent IL-10 secretion.
The molecular dissection of the transla-
tion of these quantitative differences
(high versus low IL-12 production by DC)
into a qualitative NK cell transition
(presence or absence of IL-10 production
by NK cells) is of major interest and
remains to be explored. Of note, IL-10 is
a member of a group of cytokines that
also includes IL-19, IL-20, IL-22, IL-24,
IL-26, and interferon-ls (IL-28a, IL-28b,
and IL-29). Very recently, a subset of cells
with properties common to both lymphoid
tissue-inducer cells and NK cells has
been described in humans and mice to
produce IL-22 upon IL-23 stimulation
(Vivier et al., 2009). Therefore, two related
cytokines, IL-12 (IL-12p40:IL-12p35) and
IL-23 (IL-12p40:IL-23p19), induce NK
cells and NK-related cells to produce
cytokines belonging to the same group,
IL-10 and IL-22, consistent with a
common evolution of these regulatory
loops.
In humans, IL-10 production by NK
cells is detected in patients with hepatitis
C virus infection (De Maria et al., 2007). Inecember 17, 2009 ª2009 Elsevier Inc. 493
Figure 1. NK Cells as Regulatory Cells
NK cell effector function is dependent upon their interaction with myeloid cells such as antigen-presenting
cells (APCs) (e.g., DC and macrophages). IL-12, originally described as an NK-stimulating factor, is
produced by APC and is a potent inducer of NK INF-g. Under conditions of systemic inflammation,
such as during the course of disseminated pathogenic infection (with Toxoplasma gondii, Listeria mono-
cytogenes, or Yersinia pestis), high IL-12 production leads to both IFN-g and IL-10 production by NK cells,
but the net outcome of this response might be in favor of the immunosuppressive function of IL-10 on APC
and T cell responses. It remains to be explored whether IL-10 secretion by NK cells influences B cell
responses, target cell sensitivity to NK cells, and NK cell effector functions in a paracrine loop. Under
conditions of localized inflammation, such as during influenza virus or attenuated Yersinia pestis intranasal
infection, low IL-12 production only triggers IFN-g production by NK cells, leading to a positive feeedback
loop between NK cells and APC.
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secreting human NK cells on antigen-
specific CD4+ T cell proliferation has
been reported (Deniz et al., 2008). In this
experimental setting, only a minor fraction
of NK cells were capable of producing IL-
10 ex vivo, suggesting the specialization
of a subset of NK cells for the secretion
of IL-10. These data contrast with the
large percentage of IL-10-producing NK
cells detected by Perona-Wright and
colleagues upon in vivo infection
(Perona-Wright et al., 2009). It remains
to be investigated whether the bicistronic
IL-10-GFP reporter mice used by Perona-
Wright and colleagues to measure the
frequency of IL-10-producing NK cells
upon microbial infection faithfully mirror
the production of IL-10 by NK cells, or
whether human versus mouse differences
and/or variation in cell stimulation
account for this discrepancy.494 Cell Host & Microbe 6, December 17, 200The paucity of nonambiguous cases of
NK-selective deficiencies in humans has
hampered the identification of nonredun-
dant NK cell function. Yet most NK cell
studies in mice and humans emphasize
the protective role of NK cells against
viruses and cancer (Vivier et al., 2008).
Besides their effector function against
microbe-infected cells and tumor cells, it
has been recently appreciated that NK
cells can also induce the lysis of activated
macrophages and T cells, and shape
the Th1 orientation of the CD4+ T cell
response via their production of IFN-g.
The production of IL-10 by NK cells thus
adds to the emerging notion that NK
cells can exert regulatory function, and
prompts analysis of new scenarios that
might be relevant to NK cell function
in vivo. First, do NK cell defects that could
lead to a diminished IL-10 secretion cause
an exacerbation of inflammatory and9 ª2009 Elsevier Inc.immunopathology reactions? Second, is
it possible that the production of IL-10
by NK cells contributes to the compro-
mised immunity that is associated with
conditions of chronic inflammation? In
particular, IL-10 has been associated
with tumor progression, and the chronic
stimulation of NK cells by tumor cells
might lead to an impairment of the
antitumor response at the tumor bed.
Answers to these questions might lead
to new rationales in the design of immuno-
therapeutics. Indeed, if IL-10-secreting
NK cells are deleterious to the host, NK
cell selective depletion could be set up
in vivo in humans. Along this line, preclin-
ical mouse studies have shown that NK
cell depletion increases survival in exper-
imental sepsis. NK cell monitoring in
clinical conditions is classically restricted
to the analysis of their cell-surface pheno-
type, in vitro cytotoxicity, and IFN-g
production. The recent studies on IL-10
unveil an immunosuppressive function of
NK cells and prompt the assay of human
NK IL-10 ex vivo. Finally, it will be of
interest to test whether the production of
IL-10 by NK cells might influence their res-
ponse locally, as IL-10 has been shown to
promote the sensitivity of target cells to
NK cells (Petersson et al., 1998). Further-
more, the paracrine effect of IL-10 might
also be worth addressing, as in contrast
to its broad immunosuppressive func-
tion, IL-10 can boost NK cell effector
responses (Cai et al., 1999) (Figure 1).
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Hepatitis C virus (HCV) is resistant to the antiviral cytokine type I interferon, representing a major clinical
problem. Garaigorta and Chisari (2009) reveal that HCV uses the activation of the ds-RNA-dependent protein
kinase R, which phosphorylates and inhibits the translation initiation factor eIF-2a, to block translation of
interferon-stimulated genes.Hepatitis C virus (HCV) infection is a major
cause of chronic hepatitis, liver cirrhosis,
and hepatocellular carcinoma. With
more than 170 million people chronically
infected by HCV worldwide, this disease
has emerged as a serious global health
problem (Alter and Seeff, 2000). There is
no vaccine available, and the only means
to control the disease is through antiviral
therapy, largely by the combination of
type I interferon (IFN) and ribavirin.
However, this antiviral therapy, though
effective, has limited success, and many
individuals become nonresponsive.
Monotherapy based on IFN alone is inef-
fective in the majority of HCV-infected
patients. Although multiple mechanisms
have been proposed for how HCV coun-
teracts the antiviral effects of IFN, the
basis of HCV’s resistance to IFN therapy
is not clear (Feld and Hoofnagle, 2005).
Several HCV proteins inhibit JAK-STAT
signaling, NS5A inhibits IL-8 induction,
and HCV core protein inhibits the induc-
tion of SOCS-3 and transcriptionally
suppresses interferon-stimulated genes
(ISGs). Also, NS5A, E2, and the presence
of an internal ribosome entry site (IRES) in
the HCV genome serve to overcome the
translation-inhibiting function of the eIF-
2a kinase, PKR (Wohnsland et al., 2007).The cell culture system for productive
HCV infection (Zhong et al., 2006) allows
more direct measurements of the effects
of IFN during the lifecycle of the virus.
Although IFN induces ISGs in the liver,
HCV infection still persists, and it was
previously suggested that HCV might
block the effector functions of ISGs in
the infected cells (Alter and Seeff, 2000).
In the current issue of Cell Host &
Microbe, Garaigorta and Chisari (2009)
have addressed the question of IFN-resis-
tant mechanisms of HCV using the cell
culture model based on the hepatic cell
line Huh-7 infected with HCV. A compar-
ison between the effects of IFN on full-
length replicon cells versus persistently
infected cells revealed a clear distinction,
with replicon cells being more sensitive to
IFN effects than the persistent infection,
as previously noted. However, in the
context of persistent infection and under
conditions in which IFN treatment had
little effect on intracellular HCV RNA or
proteins, virus-infected cells produced
many fewer ISGs (i.e., MxA and ISG15),
and this effect was posttranscriptional
because ISG mRNA levels were not
affected. Pulse-labeling experiments
showed that, whereas HCV infection had
little effect on global host cell proteinsynthesis, treatment with IFN inhibited
protein translation in a dose-dependent
manner. Because eIF-2a, a key transla-
tional regulator, is phosphorylated by the
ds-RNA-dependent kinase PKR, which
downregulates its activity (Garcı´a et al.,
2006), an examination of the kinetics of
virus infection revealed that HCV infection
is accompanied by phosphorylation of
PKR and of eIF-2a, although viral protein
accumulation is not altered. Other eIF-2a
kinases, namely PERK and GCN2, were
not involved, and the process was type I
IFN independent. Both PKR and eIF-2a
phosphorylation were more strongly
induced in IFN-treated HCV infected cells,
although the accumulation of HCV RNA
was not impaired. Further, HCV replica-
tion was also not affected in infected cells
expressing short hairpin RNA to block
PKR expression. However, upon PKR
depletion by siRNA, HCV infection
became more sensitive to the antiviral
effects of IFN. In these PKR-depleted
cells, ISG protein expression was re-
stored, correlating with an enhanced
reduction of HCV RNA indicating that
ISG proteins mediate the antiviral effects
of IFN. Overall, the work of Garaigorta
and Chisari suggests that HCV-induced
PKR phosphorylation is responsible forecember 17, 2009 ª2009 Elsevier Inc. 495
